B

Binex Co Ltd
KOSDAQ:053030

Watchlist Manager
Binex Co Ltd
KOSDAQ:053030
Watchlist
Price: 15 730 KRW 1.48% Market Closed
Market Cap: 514.1B KRW
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Binex Co Ltd stock under the Base Case scenario is 9 193.97 KRW. Compared to the current market price of 15 730 KRW, Binex Co Ltd is Overvalued by 42%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
9 193.97 KRW
Overvaluation 42%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Valuation Multiples

3.9
P/S
P/S
Price to Sales
3.9
vs History
38
vs Industry
30
Median 3Y
2.4
Median 5Y
3.5
Industry
2.4
Forward
2.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
3
Median 3Y
19.4
Median 5Y
26.9
Industry
20.3
Forward
37.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
3
Median 3Y
13.6
Median 5Y
20.9
Industry
15.6
More Details
66.7
P/FCFE
P/FCFE
Price to FCFE
66.7
vs History
23
vs Industry
7
Median 3Y
-20.1
Median 5Y
-10.7
Industry
23.1
More Details
2.8
P/B
P/B
Price to Book Value
2.8
vs History
38
vs Industry
25
Median 3Y
2.2
Median 5Y
2.7
Industry
2
More Details
4.1
EV/S
EV/S
Enterprise Value to Sales
4.1
vs History
36
vs Industry
27
Median 3Y
2.2
Median 5Y
3.4
Industry
2.5
Forward
2.8
More Details
25.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
25.3
vs History
9
vs Industry
7
Median 3Y
5.8
Median 5Y
8.5
Industry
4.8
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
7
Median 3Y
10.3
Median 5Y
15
Industry
12.5
Forward
26.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
0
Median 3Y
13.1
Median 5Y
30.2
Industry
15.7
Forward
39
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
2
Median 3Y
13.9
Median 5Y
19.4
Industry
14.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-26.9
Median 5Y
-20.4
Industry
17.6
More Details
2.2
EV/IC
EV/IC
Enterprise Value to IC
2.2
vs History
39
vs Industry
31
Median 3Y
1.7
Median 5Y
2.1
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Binex Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Binex Co Ltd
KOSDAQ:053030
501B KRW 3.9 -14.3 -29.4 -17.5
US
Eli Lilly and Co
NYSE:LLY
778.5B USD 15.9 70.1 37.6 41.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.9B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.9 19.8 13.1 14.9
CH
Roche Holding AG
SIX:ROG
216.2B CHF 3.6 26.1 9.8 11.5
UK
AstraZeneca PLC
LSE:AZN
168.2B GBP 4.1 28.7 131 197.5
CH
Novartis AG
SIX:NOVN
181.6B CHF 4.1 17.1 10.1 13.6
US
Merck & Co Inc
NYSE:MRK
209.4B USD 3.3 12 8.6 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
120.9B EUR 1.3 9.5 5.2 6.2
P/E Multiple
Earnings Growth PEG
KR
B
Binex Co Ltd
KOSDAQ:053030
Average P/E: 25.1
Negative Multiple: -14.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
70.1
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.8
18%
1.1
CH
Roche Holding AG
SIX:ROG
26.1
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
28.7
36%
0.8
CH
Novartis AG
SIX:NOVN
17.1
17%
1
US
Merck & Co Inc
NYSE:MRK
12
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.5
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
B
Binex Co Ltd
KOSDAQ:053030
Average EV/EBITDA: 433.6
Negative Multiple: -29.4 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.6
31%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.8
6%
1.6
UK
AstraZeneca PLC
LSE:AZN
131
9%
14.6
CH
Novartis AG
SIX:NOVN
10.1
5%
2
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.2
8%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
B
Binex Co Ltd
KOSDAQ:053030
Average EV/EBIT: 1 866.9
Negative Multiple: -17.5 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41.1
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.9
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
197.5
21%
9.4
CH
Novartis AG
SIX:NOVN
13.6
10%
1.4
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
6.2
14%
0.4

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 252,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.